CY1124153T1 - Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127 - Google Patents

Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127

Info

Publication number
CY1124153T1
CY1124153T1 CY20211100394T CY211100394T CY1124153T1 CY 1124153 T1 CY1124153 T1 CY 1124153T1 CY 20211100394 T CY20211100394 T CY 20211100394T CY 211100394 T CY211100394 T CY 211100394T CY 1124153 T1 CY1124153 T1 CY 1124153T1
Authority
CY
Cyprus
Prior art keywords
antibodies
directed against
polypeptides directed
diagnostic applications
therapeutic
Prior art date
Application number
CY20211100394T
Other languages
English (en)
Inventor
Nicolas Poirier
Caroline Mary
Bernard Vanhove
Virginie THEPENIER
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of CY1124153T1 publication Critical patent/CY1124153T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση ανήκει στο πεδίο των αντισωμάτων χρήσιμων σε θεραπευτικές και διαγνωστικές εφαρμογές που στοχεύουν σε CD127, την άλφα αλυσίδα του υποδοχέα IL7, και παρέχει ιδιαίτερα εξανθρωπισμένα μονοκλωνικά αντισώματα έναντι CD 127, ιδιαίτερα έναντι ανθρώπινου CD 127, θεραπευτικές χρήσεις αυτών, και διαγνωστικές εφαρμογές.
CY20211100394T 2016-12-09 2021-05-07 Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127 CY1124153T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306655 2016-12-09
PCT/EP2017/081911 WO2018104483A1 (en) 2016-12-09 2017-12-07 Antibodies and polypeptides directed against cd127

Publications (1)

Publication Number Publication Date
CY1124153T1 true CY1124153T1 (el) 2022-05-27

Family

ID=57796143

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100394T CY1124153T1 (el) 2016-12-09 2021-05-07 Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127

Country Status (37)

Country Link
US (2) US11098128B2 (el)
EP (1) EP3551664B1 (el)
JP (1) JP6986559B2 (el)
KR (1) KR102306366B1 (el)
CN (1) CN110392695B (el)
AR (1) AR110326A1 (el)
AU (1) AU2017373819B2 (el)
BR (1) BR112019010595A2 (el)
CA (1) CA3042582C (el)
CL (1) CL2019001530A1 (el)
CO (1) CO2019005909A2 (el)
CR (1) CR20190273A (el)
CY (1) CY1124153T1 (el)
DK (1) DK3551664T3 (el)
EA (1) EA201991005A1 (el)
ES (1) ES2867900T3 (el)
HR (1) HRP20210697T1 (el)
HU (1) HUE054206T2 (el)
IL (1) IL266837B (el)
LT (1) LT3551664T (el)
MA (1) MA49727B1 (el)
MD (1) MD3551664T2 (el)
MX (1) MX2019006577A (el)
MY (1) MY190770A (el)
NZ (1) NZ753213A (el)
PE (1) PE20191152A1 (el)
PH (1) PH12019501285A1 (el)
PL (1) PL3551664T3 (el)
PT (1) PT3551664T (el)
RS (1) RS61808B1 (el)
RU (1) RU2769352C2 (el)
SA (1) SA519401906B1 (el)
SI (1) SI3551664T1 (el)
TW (1) TWI777996B (el)
UA (1) UA126386C2 (el)
UY (1) UY37511A (el)
WO (1) WO2018104483A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7348074B2 (ja) 2017-06-04 2023-09-20 ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズ がん治療に対する個別化応答の予測方法およびそのキット
BR112021014106A2 (pt) 2019-01-22 2021-10-13 Bristol-Myers Squibb Company Anticorpos contra subunidade alfa de il-7r e usos dos mesmos
MX2021015761A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
CN114514243A (zh) 2019-06-21 2022-05-17 索瑞索制药公司 多肽
WO2021092075A1 (en) 2019-11-05 2021-05-14 Medikine Inc. IL-2RβγC BINDING COMPOUNDS
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
WO2021158623A1 (en) 2020-02-03 2021-08-12 Medikine, Inc. IL-7Rαγc BINDING COMPOUNDS
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
CN113501499A (zh) * 2021-08-11 2021-10-15 无锡贝塔医药科技有限公司 一种高纯无水溴化氘气体的制备方法及其应用
WO2023232826A1 (en) 2022-05-30 2023-12-07 Ose Immunotherapeutics Biomarkers of il7r modulator activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32038A (es) * 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
EP2528947A4 (en) 2010-01-28 2013-09-18 Glaxo Group Ltd CD127 BINDING PROTEINS
TWI596114B (zh) * 2010-02-24 2017-08-21 雷那特神經科學股份有限公司 拮抗劑抗-ｉｌ-７受體抗體及方法
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
EA201991005A1 (ru) 2019-12-30
MA49727B1 (fr) 2021-05-31
RS61808B1 (sr) 2021-06-30
ES2867900T3 (es) 2021-10-21
WO2018104483A1 (en) 2018-06-14
HUE054206T2 (hu) 2021-08-30
RU2019115610A (ru) 2021-01-12
PH12019501285A1 (en) 2019-12-16
AU2017373819A1 (en) 2019-05-30
UY37511A (es) 2018-06-29
TW201833137A (zh) 2018-09-16
US20190375844A1 (en) 2019-12-12
CO2019005909A2 (es) 2019-07-31
EP3551664A1 (en) 2019-10-16
SI3551664T1 (sl) 2021-08-31
JP2020500542A (ja) 2020-01-16
RU2019115610A3 (el) 2021-04-05
SA519401906B1 (ar) 2022-12-20
CN110392695A (zh) 2019-10-29
PE20191152A1 (es) 2019-09-05
CA3042582C (en) 2023-05-23
MY190770A (en) 2022-05-12
PL3551664T3 (pl) 2021-08-02
MA49727A (fr) 2019-10-16
EP3551664B1 (en) 2021-02-17
KR20190090005A (ko) 2019-07-31
US20210395376A1 (en) 2021-12-23
MX2019006577A (es) 2019-10-07
AR110326A1 (es) 2019-03-20
CA3042582A1 (en) 2018-06-14
MD3551664T2 (ro) 2021-06-30
RU2769352C2 (ru) 2022-03-30
CN110392695B (zh) 2021-02-02
HRP20210697T1 (hr) 2021-07-23
IL266837B (en) 2020-06-30
TWI777996B (zh) 2022-09-21
KR102306366B1 (ko) 2021-09-29
US20220332834A2 (en) 2022-10-20
UA126386C2 (uk) 2022-09-28
JP6986559B2 (ja) 2022-01-05
CR20190273A (es) 2019-10-17
US11098128B2 (en) 2021-08-24
PT3551664T (pt) 2021-04-21
DK3551664T3 (da) 2021-05-03
LT3551664T (lt) 2021-05-25
BR112019010595A2 (pt) 2019-09-17
US11926671B2 (en) 2024-03-12
AU2017373819B2 (en) 2022-03-31
IL266837A (en) 2019-07-31
NZ753213A (en) 2022-05-27
CL2019001530A1 (es) 2019-10-11

Similar Documents

Publication Publication Date Title
CY1124153T1 (el) Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
CY1123783T1 (el) Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CY1124096T1 (el) Αντισωματα τα οποια στοχευουν αντιγονο ωριμανσης β-κυτταρων και μεθοδοι χρησης
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
EA201892294A1 (ru) Антитела и композиции против tim-3
SA518391722B1 (ar) أجسام مضادة تستهدف شبيه مستقبل Fc5 وطرق استخدامها
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201792221A1 (ru) Антитела против сортилина и способы их применения
CL2016001716A1 (es) Anticuerpo moléculas de tim-3 y usos de los mismos
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CY1124922T1 (el) Καινοτομος σταθερη φαρμακοτεχνικη μορφη για αντισωματα fxia
EA201592285A1 (ru) Антигенсвязывающие белки к рецептору онкостатина м
CL2021000258A1 (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ